Where is Partex.AI located?

Partex.AI is headquartered in Eschborn, Germany.

Who is the current CEO of Partex.AI?

Lakshmi Mohan and Gunjan Govind Bhardwaj s of Partex.AI. Lakshmi Mohan has also founded 1 company.

Which legal entities is Partex.AI associated with?

Partex.AI is associated with Partex.AI Labs GmbH.

How many employees does Partex.AI have?

As of May 31, 2026, the latest employee count at Partex.AI is 197.

Is Partex.AI a funded company?

Partex.AI is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Partex.AI rank among its competitors?

Partex.AI ranks 107th amongst 178 active competitors, of which 68 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of Partex.AI?

Partex.AI's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

Partex.AI - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Provider of AI-powered solutions to optimize drug discovery and development. The company focuses on identifying and developing late-stage preclinical and early clinical drug assets. It offers services to unlock value from deprioritized drug assets through AI-driven in- and out-licensing. The company develops functional assays and high-throughput experimental screening to confirm AI-driven predictions. It also builds partnerships to leverage real-world data for drug development and treatment optimization.

Website: partex.ai/en
Email ID: *****@partex.ai

Key Metrics

Founded Year

2011

Location

Eschborn, Germany

Stage

Funding Raised

Investors

100Unicorns

Ranked

107^th among 178 active competitors

Employee Count

197 as on May 31, 2026

Similar Companies

Schrodinger & 207 more

View Partex.AI's full profile

Partex.AI is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Partex.AI Labs GmbH CIN: DED3410V.HRB15481 , Germany, Active	Jul 20, 2016	-	-

Partex.AI is a funded company. Partex.AI has 1 institutional investor.

View details of Partex.AI's funding rounds and investors

The founders of Partex.AI are Robert Dube, Lakshmi Mohan, Gunjan Govind Bhardwaj, Robert Dube, Robert Dube and Gaurav Tripathi. Lakshmi Mohan and Gunjan Govind Bhardwaj are the CEOs of Partex.AI.

Here are the details of Partex.AI's key team members:

Robert Dube: Owner of Partex.AI.
Lakshmi Mohan: Co-Founder & CEO (Partex AI - Real World Data) of Partex.AI.
Gunjan Govind Bhardwaj: Co-Founder & CEO of Partex.AI.
Robert Dube: Owner of Partex.AI.
Robert Dube: Owner of Partex.AI.

View details of Partex.AI's Founder profiles and Board Members

Partex.AI's employee count trend

Partex.AI has 197 employees as of May 26. Here is Partex.AI's employee count trend over the years:

Uncover Partex.AI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Partex.AI include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of Partex.AI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 47 others	72/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, HSG & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, CapitalG & 6 others	64/100
5th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	Index Ventures, Iconiq Capital & 14 others	63/100
6th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
7th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
8th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
9th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Prosperity7 Ventures ... & 36 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Balderton Capital & 18 others	62/100
107th	Partex.AI 2011, Eschborn (Germany), Funding Raised	Provider of AI-powered solutions to optimize drug discovery and development	-	100Unicorns	26/100